Silybum marianum (L.) Gaertn. — The most extensively documented hepatoprotective medicinal plant in Western phytomedicine, whose seed complex silymarin is used globally for liver support, amatoxin poisoning, and adjunctive cancer care.
Silybum marianum is a biennial thistle native to the Mediterranean basin, producing black achenes (fruit) containing 1.5–3% silymarin — one of the most mechanistically characterised hepatoprotective phytocomplexes in modern medicine. Silymarin's principal constituent, silibinin, acts as both a membrane stabiliser and a nuclear regulatory agent, giving the plant a uniquely dual mechanism among liver-protective botanicals.
Silybum marianum is a robust biennial herb growing to 1.5 metres in height. Its most distinctive feature is the large, deep-green leaves whose veins are conspicuously marbled with white — a pattern of ethnobotanical significance for centuries. The leaf margins are deeply lobed and armed with sharp, yellow-tipped spines. Large capitula (flower heads) of violet-mauve colour measure 3–8 cm across, enclosed by strongly spiny bracts.
The plant thrives on disturbed, uncultivated ground and is naturalised across Southern and Central Europe, the Mediterranean basin, North Africa, and Western Asia. It has also become widely naturalised in the Americas and Australia. The medicinal part is the fruit: a black, rough achene of 6–7 mm by 3 mm, bearing a remnant floral crown in the form of a pale yellow cylindrical scale.
Etymology & Folk Legend
According to popular tradition, the white marbling on the leaves arose from drops of the Virgin Mary's milk falling onto the plant while nursing the infant Jesus — hence the English name "milk thistle" and the Latin species epithet marianum. The French chardon-Marie and German Mariendistel share the same Marian etymology.
Pharmacopoeia Status
Both the leaf and fruit of Silybum marianum appear on List A of the French Pharmacopoeia (Pharmacopée Française), recognising official medicinal status. The standardised extract Légalon® (providing 70 mg silymarin per tablet) is registered as a pharmaceutical in several European countries.
Milk thistle has been a fixture of European herbalism for over two millennia. Classical physicians used all aerial parts for liver and biliary complaints; it was Dioscorides who first explicitly linked the plant to the treatment of liver disorders, a use that would be vindicated by twentieth-century phytochemistry with the isolation of silymarin.
Dioscorides (1st century CE) and Pliny the Elder described milk thistle as a remedy for liver ailments. The plant was one of the primary hepatic botanicals in the Graeco-Roman materia medica, used to counter biliary obstructions and jaundice.
The plant's white-veined leaves were interpreted as a divine sign of its galactogenic properties, and milk thistle was commonly prescribed by monastic herbalists to nursing mothers to stimulate milk production — a use now partially supported by evidence of hyperprolactinaemic effects in animal models.
North American Eclectic physicians adopted milk thistle for congestion of the liver, spleen, and kidneys. The homeopathic mother tincture of Carduus marianus fruit became the form of choice, used for hepatic and portal congestion with jaundice.
Silymarin was isolated and characterised in the 1960s by German researchers. The standardised extract Légalon® entered European markets in the 1970s. Subsequent decades yielded hundreds of experimental and clinical studies confirming hepatoprotective, antiviral, anticancer, and immunomodulatory properties, making milk thistle among the most scientifically investigated medicinal plants globally.
Clinical Landmark
"A randomised controlled trial of silymarin treatment in patients with cirrhosis showed a significant improvement in survival duration."
Ferenci et al., J Hepatol — Ref [20]
The 1989 Ferenci trial remains one of the most cited RCTs in hepatic phytomedicine, demonstrating that silymarin can meaningfully extend survival in cirrhotic patients — a finding that firmly established milk thistle as a clinically serious hepatoprotective agent rather than a folk remedy.
The fruit (achene) is the sole medicinal part. Standardised dry extracts delivering a defined silymarin dose are clinically preferred over tinctures and infusions, which provide insufficient flavonolignan concentration for a marked hepatoprotective effect.
The homeopathic mother tincture of Carduus marianus fruit and fluid extract are traditional forms. However, both deliver insufficient silymarin per therapeutic dose to replicate the hepatoprotective effects observed with standardised preparations — clinical use is limited.
The benchmark pharmaceutical preparation is Légalon® (fruit extract standardised to 70 mg silymarin per tablet), used in the pivotal European clinical trials. Administered as 2 tablets 2–3 times daily; most robust clinical results use 140 mg silymarin three times per day (420 mg/day total).
EPS (standardised aqueous-glycerol extract) is a modern phytopharmaceutical form. The silybin-phosphatidylcholine complex (Siliphos®) exploits phospholipid complexation to substantially enhance silymarin oral bioavailability and tissue distribution compared to conventional extracts. [47]
The fruit of Silybum marianum contains a unique flavonolignan complex — silymarin — as well as classical flavonoids, phenolic derivatives, sterols, tocopherol, and a high proportion of fixed oil. No essential oil or bud constituents have been pharmacologically characterised in the primary source.
Dual Mechanism
Silymarin acts simultaneously as a hepatocyte membrane stabiliser (blocking toxin transporters) and as a nuclear regulatory agent (stimulating RNA Polymerase I and ribosomal RNA synthesis).
Bioavailability Challenge
Standard silymarin has limited oral bioavailability due to poor water solubility. Complexation with phosphatidylcholine (Siliphos®) significantly improves absorption and tissue penetration.
Pharmacokinetics
Peak plasma concentration at 2–6 hours post-ingestion; elimination half-life ≈ 6 hours. Mainly excreted in bile and faeces, enabling enterohepatic recirculation.
Silymarin exerts broad hepatoprotective activity via membrane stabilisation, antioxidant effects, inhibition of TNF-alpha and selectins, suppression of NF-κB, inhibition of inducible nitric oxide synthase (iNOS), modulation of lipoxygenase pathways, and reduction of collagen synthesis. Effects are mediated at the level of DNA and RNA. [1],[2],[3],[4],[5],[6]
Silymarin inhibits hepatocyte membrane transport systems, reducing toxic substance uptake. It prevents lipid peroxidation [7] and preserves the glutathione pool responsible for hepatic phase-2 detoxification, protecting against oxidative stress. It reduces transaminase and alkaline phosphatase elevation. [8]
Silymarin stimulates RNA Polymerase I (DNA polymerase A) activity, increasing ribosomal RNA synthesis and the number of hepatocyte ribosomes. This enhances enzymatic biosynthesis, protein synthesis, and the liver's regenerative capacity — a mechanism particularly relevant in toxic and cirrhotic injury.
Silymarin prevents and treats hepatotoxicity induced by carbon tetrachloride [9], galactosamine [10], and phalloidin. [11],[12],[13],[14] Protection is greatest when silymarin is administered prophylactically, before hepatotoxin exposure.
Silibinin is clinically used as an antidote for death cap mushroom poisoning. A meta-analysis of 452 patients showed mortality of 9.8% with silibinin versus 18.3% with standard treatment (p <0.01). [16] It blocks amatoxin uptake by hepatocytes and stimulates RNA polymerase. [17],[18],[19]
A randomised controlled trial demonstrated that silymarin significantly improved survival duration in patients with cirrhosis of the liver compared to placebo — one of the strongest clinical demonstrations of hepatoprotective efficacy for any phytomedicine. [20]
Silibinin is a potent direct inhibitor of HCV RNA-dependent RNA polymerase. [23] Clinical studies show antiviral activity in pegylated interferon/ribavirin non-responders [22] and viral kinetic modelling has confirmed silibinin's multi-modal action against HCV. [21]
Synergistic combinations of Cynara scolymus, Silybum marianum, and Cochlospermum angolense show anti-hepatocellular carcinoma activity in preclinical models, with additive antioxidant and antiproliferative effects. [24]
Silibinin and silychristin from milk thistle stimulate kidney cell function and protein synthesis in preclinical models, demonstrating direct nephroprotective activity. [25] Silymarin also selectively reduces cisplatin-induced renal cytotoxicity in human renal cells. [43]
Milk thistle extracts raise serum prolactin levels in female rats (hyperprolactinaemic effect) [26],[27], supporting its long traditional use as a galactogogue (lactation stimulant). The phytotherapy implication for nursing mothers is also supported by ethnobotanical and emerging clinical data. [28]
Silymarin exerts anti-cancer activity at stages of initiation, promotion, and progression of carcinogenesis, with notable anti-metastatic effects. Multiple clinical studies demonstrate reduction in chemotherapy-related toxicity when silymarin is co-administered. [29],[30],[31]
Silymarin and its flavonolignan components (silybin A, silybin B, isosilybin A, isosilybin B) inhibit prostate cancer cell proliferation and angiogenesis, targeting VEGF–VEGFR signalling, phospho-Akt, and HIF-1α. [32],[33],[34],[35],[36]
Silymarin inhibits tumour cell proliferation in ovarian [37], breast [38], lung [39], skin [40], and bladder [41],[42] carcinoma cell lines. Mechanisms include G1 cell cycle arrest, apoptosis induction via caspase-3 and PARP cleavage, and CDK–cyclin cascade regulation.
Silymarin inhibits T-cell cycle progression and mTOR activity in activated human T cells, suppressing mitogen-activated protein kinase (MAPK) signalling and reducing cytokine production (TNF-α, IFN-γ, IL-2, IL-4). These effects suggest therapeutic potential in autoimmune disease. [44],[45],[46]
Silybum marianum demonstrates hypoglycaemic activity in an animal model of type 1 diabetes, showing potential for adjunctive use in blood glucose regulation. [48] The plant also shows benefit in hepatic iron overload and haemochromatosis. [57]
A randomised triple-blind clinical trial in primiparous women demonstrated that Silybum marianum ointment significantly accelerated episiotomy wound healing and reduced pain intensity compared to placebo. [49]
The fixed oil extracted from milk thistle seeds — a by-product of silymarin production — independently exhibits antioxidant properties and attenuates mitochondrial dysfunction in galactose-challenged mice, suggesting secondary metabolite value beyond the flavonolignan fraction. [50]
Combining silymarin with phosphatidylcholine in a phytosome complex (Siliphos®) substantially increases oral absorption and clinical efficacy compared to standard silymarin extract, addressing a key limitation of conventional milk thistle preparations. [47]
Silymarin's neuroprotective, anti-inflammatory, and antioxidant mechanisms suggest activity against neurodegeneration. Preclinical evidence supports potential roles in Alzheimer's disease, Parkinson's disease, and diabetic complications, though clinical evidence remains limited. [56]
Milk thistle has been reported to possess antidepressant properties, attributed in part to its effects on neuroinflammation and oxidative stress pathways in the CNS, though clinical evidence is currently limited to preclinical and mechanistic data.
Silybin acts as a novel iron-chelating agent, reducing intracellular labile iron pools. This property underpins its clinical utility in hepatic iron overload conditions such as haemochromatosis and iron-accumulating liver disease. [57]
Indications are based on phytotherapy of the whole plant (fruit extract). No bud (gemmotherapy) or essential oil indications are documented for Silybum marianum.
Formulation matters: Infusions and alcoholic tinctures deliver insufficient silymarin for a clinically significant hepatoprotective effect. The standard dose is 12–15 g of crude drug per day, but the most effective regimens in RCTs used 140 mg standardised silymarin three times daily. If crude drug contains only 2% silymarin, 21 g/day would be required to reach this dose. Standardised dry extracts (Légalon® or equivalent) are therefore strongly preferred for liver indications. The silybin-phosphatidylcholine complex further improves bioavailability. [47]
Silymarin's phenolic hydroxyl groups directly scavenge reactive oxygen species (ROS) including hydroxyl radicals, superoxide anions, and hypochlorous acid. This broad-spectrum antioxidant activity rapidly reduces oxidative stress, preventing protein oxidation, lipid peroxidation, and DNA strand breaks. Silymarin also preserves mitochondrial integrity by stabilising electron transport chain complexes. [7],[8]
Silymarin is incorporated into the hydrophobic–hydrophilic interface of the hepatocyte plasma membrane bilayer, increasing membrane stability and reducing its permeability to xenobiotics. It specifically inhibits hepatocyte membrane transporter systems — including OATPs and OCTs — blocking cellular uptake of hepatotoxins such as amatoxins and phalloidin. This barrier function is the principal mechanism underlying its antidote action in Amanita poisoning. [11],[17]
Silymarin maintains the hepatic glutathione pool — the cell's primary antioxidant defence — by increasing cysteine availability and upregulating glutathione synthesis. It activates the Nrf2/ARE transcriptional pathway, driving expression of antioxidant enzymes including glutathione peroxidase and superoxide dismutase. This sustains phase-2 detoxification capacity and protects against drug- and toxin-induced liver injury. [8]
Silymarin stimulates RNA Polymerase I (DNA-dependent RNA polymerase / DNA polymerase A) in hepatocytes, increasing ribosomal RNA synthesis. This elevates the number of ribosomes and enhances both enzymatic biosynthesis and total protein synthesis — directly accelerating hepatocyte regeneration after toxic or ischaemic injury. This nuclear regulatory mechanism is unique among hepatoprotective phytomedicines. [17],[19]
Silymarin suppresses nuclear factor kappa B (NF-κB) activation, reducing expression of pro-inflammatory genes. It inhibits production of TNF-α, IFN-γ, IL-2, and IL-4, and decreases leukotriene synthesis via 5-lipoxygenase inhibition in hepatic Kupffer cells. Inhibition of inducible nitric oxide synthase (iNOS) further limits inflammatory nitrosative stress. [6]
Silymarin reduces hepatic collagen synthesis and deposition, inhibiting the stellate cell activation pathways responsible for progressive fibrosis. This anti-fibrotic action is central to its survival benefit in cirrhosis, preventing the structural remodelling that ultimately leads to hepatic failure. Modulation of TGF-β signalling is implicated in this mechanism.
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase (NS5B), blocking viral replication independently of immune modulation. This mechanism is clinically relevant in HCV-infected patients who have failed interferon-based regimens, positioning IV silibinin as a direct-acting antiviral in selected cases. [23],[58]
Silymarin inhibits T-cell cycle progression by suppressing mTOR activity and MAPK (mitogen-activated protein kinase) signalling in activated human T lymphocytes, reducing cytokine output and T-cell proliferation. This immunosuppressive mechanism is distinct from its hepatoprotective actions and underlies the proposed therapeutic potential in autoimmune diseases. [44],[45],[46]
Silibinin targets multiple cancer-proliferative pathways simultaneously: tyrosine kinase receptors, androgen receptors, STAT (signal transducers and activators of transcription), NF-κB, CDK–cyclin cell cycle regulatory pathways, and apoptotic signalling cascades. Anti-metastatic effects involve modulation of specific proteins including VEGF–VEGFR, HIF-1α, and phospho-Akt in tumour vasculature. [53],[54]
Silymarin inhibits cytochrome P-450 enzyme activity (notably CYP3A4 and CYP2C9) and reduces UDP-glucuronosyltransferase (UGT1A6/9) and P-glycoprotein (P-gp) transport activity. This alters hepatic drug metabolism and can affect the pharmacokinetics of co-administered drugs — a clinically significant interaction mechanism requiring awareness in polypharmacy. [61],[62]
The traditional homeopathic mother tincture prepared from fresh or dried milk thistle fruit. Delivers limited silymarin per therapeutic dose and is insufficient for a marked hepatoprotective effect at standard tincture volumes. Historical use persists for mild biliary and digestive complaints.
A more concentrated liquid preparation than the mother tincture. Still unlikely to deliver the 140–420 mg/day silymarin required for clinical liver outcomes demonstrated in RCTs. May be used as a starting point for compounded formulations.
The benchmark pharmaceutical standardised extract. Each tablet delivers 70 mg silymarin. Dosing protocol: 2 tablets 2–3 times daily. Maximum clinical evidence achieved at 140 mg × 3 daily (420 mg/day total). Registered pharmaceutical product in several European countries. [16]
A modern integrative phytopharmaceutical form with standardised active content. EPS preparations aim to improve palatability and dosing precision while preserving the full phytocomplex, including synergistic non-silymarin constituents of the fruit.
The most bioavailable oral formulation of milk thistle. Complexation with phosphatidylcholine dramatically improves absorption across the gastrointestinal mucosa and tissue distribution, achieving superior blood levels and clinical efficacy at equivalent silybin doses compared to standard extracts. [47]
Both the leaf and the fruit of Silybum marianum are listed on List A of the Pharmacopée Française, granting official recognised medicinal status within France and informing broader European regulatory frameworks.
Intravenous silibinin (Legalon SIL®) is used in Belgium and Switzerland as an antidote for Amanita phalloides poisoning based on experimental and clinical data, even in the absence of a formally registered antidote indication in all jurisdictions. Dosing: 5 mg/kg in 5% glucose IV every 6 hours for 6 days. Source: Belgian Poison Centre. [19]
The European Medicines Agency's Committee on Herbal Medicinal Products (HMPC) has issued a positive community herbal monograph for Silybum marianum fruit dry extract standardised to silymarin, recognising its well-established medicinal use for symptomatic treatment of digestive disorders (dyspepsia) and traditional use for temporary liver dysfunction.
Milk thistle extracts are widely available as dietary supplements under DSHEA (USA) and equivalent frameworks globally. Products vary substantially in standardisation; consumers should verify silymarin content and seek third-party tested products to ensure consistent dosing.
Silymarin has an excellent acute and chronic safety profile. LD50 = 2,500 mg/kg (rat) and 5,000 mg/kg (mouse). No acute or chronic toxicity at therapeutic doses. The primary clinical concern is pharmacokinetic drug–drug interactions via CYP enzyme modulation.